Joseph Thome
Stock Analyst at TD Cowen
(0.84)
# 3,633
Out of 4,711 analysts
24
Total ratings
42.11%
Success rate
-10.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $19.03 | - | 1 | Nov 25, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Hold | n/a | $0.23 | - | 2 | Oct 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $359.58 | +11.24% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $18.07 | - | 1 | Jul 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $2.53 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $29.71 | +14.44% | 1 | Jun 17, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $83.45 | +7.85% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $2.90 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $4.05 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $46.24 | -35.12% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.28 | - | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $38.63 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.71 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.84 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $90.73 | +43.28% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.18 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.59 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.20 | - | 1 | Jul 15, 2021 |
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $19.03
Upside: -
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.23
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $359.58
Upside: +11.24%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $18.07
Upside: -
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.53
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $29.71
Upside: +14.44%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $83.45
Upside: +7.85%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $2.90
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.05
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $46.24
Upside: -35.12%
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.28
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $38.63
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $6.71
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $10.84
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $90.73
Upside: +43.28%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.18
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $17.59
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.20
Upside: -